Low-Dose CT Screening Frequency for Smokers
For eligible smokers, low-dose CT screening should be performed annually. 112
Screening Interval
The evidence consistently supports annual screening with low-dose CT (LDCT) for lung cancer in high-risk individuals. This recommendation is based on the National Lung Screening Trial (NLST) protocol, which demonstrated mortality benefit with yearly screening 11.
Who Qualifies for Annual Screening
The screening frequency applies to individuals meeting specific eligibility criteria:
Primary Eligibility (Strongest Evidence)
- Age 55-77 years
- ≥30 pack-year smoking history
- Current smokers OR quit within past 15 years
- Annual LDCT screening recommended 2
Expanded Eligibility (2021 Update)
- Age 50-80 years
- ≥20 pack-year smoking history
- Current smokers OR quit within past 15 years
- Annual LDCT screening suggested 2
Risk-Based Eligibility
For individuals not meeting the above criteria, annual screening may be offered if validated risk calculators demonstrate high net benefit, such as:
- ≥16.2 days life-gained on LYFS-CT calculator
- ≥1.33% 5-year lung cancer death risk on LCDRAT with ≥10 years life expectancy
- ≥2.0% 5-year incidence risk on LCRAT with ≥10 years life expectancy 2
Critical Implementation Points
The annual interval is non-negotiable for maintaining the mortality benefit observed in clinical trials. Screening more frequently increases false positives and radiation exposure without proven benefit. Screening less frequently may miss the window for early detection.
Important Caveats
- Screening should occur in organized programs with quality assurance in imaging and interpretation 1
- Screening should continue annually until the patient no longer meets eligibility criteria (e.g., exceeds age limit, insufficient life expectancy, or quits smoking for >15 years in some guidelines)
- Insurance coverage (including Medicare) typically requires meeting the stricter age 55-77 and ≥30 pack-year criteria 2
Common Pitfall
Do not extend screening intervals based on negative results—the evidence supporting mortality reduction is specifically tied to annual screening, not biennial or other intervals 112.